GVR Report cover North America Veterinary Oncology Market Size, Share & Trends Report

North America Veterinary Oncology Market Size, Share & Trends Analysis Report By Animal Type (Canine, Feline), By Therapy (Radiotherapy, Surgery), By Cancer Type, By Country, And Segment Forecasts, 2023 - 2033

  • Report ID: GVR-4-68040-138-7
  • Number of Pages: 150
  • Format: Electronic (PDF)
  • Historical Range: 2018 - 2021
  • Industry: Healthcare

Market Size & Trends

The North America veterinary oncology market size was estimated at USD 479.35 million in 2022 and is estimated to grow at a compound annual growth rate (CAGR) of 10.57% from 2023 to 2033. The rising adoption of veterinary cancer medicines as a viable treatment option, along with an increasing incidence of pet cancer cases is expected to drive market expansion in the coming years. The increasing inclination of owners to pay for pet healthcare services, along with government initiatives for veterinary cancer therapy have emerged as the major market drivers. The rising number of veterinary clinical trials investigating the safety and effectiveness of various oncologic therapies in pets further contributes to market growth. Moreover, increasing strategic initiatives for R&D of targeted therapies for cancer in companion animals is boosting market growth.

U.S. Veterinary Oncology market size and growth rate, 2023 - 2030

For instance, in July 2023, Ardent Animal Health partnered with FidoCure to expand access to oncology innovation in veterinary medicine by leveraging the latter's genomic testing and precision medicine platform. Such expansion efforts and the need to provide comprehensive pet care are likely to drive the market growth over the forecast period.

The COVID-19 pandemic of 2020-21 and macroeconomic headwinds of 2022-23 had a notable impact on the market with supply chain challenges, dampened growth rate, and reduced sales & marketing activities. However, the market is expected to grow notably during the forecast period as the underlying drivers continue to fuel the market growth. In June 2022, Boehringer Ingelheim entered into a research partnership with a biopharma company- CarthroniX to develop small molecule therapeutics in canine oncology.

Technological advancements related to pet cancer treatment can make the treatment easier as cancer is a dangerous disease, and most of the traditional treatment methods are painful and hard for the pets as well as the pet owner to witness it, hence some of the latest technologies such as combination therapies, precision medicine, immunotherapy, among others are preferred. For instance, in a clinical trial by UC Davis Health in 2022, dogs with metastatic lung disease resulting from osteosarcoma or melanoma were treated with protein interleukin-15 (IL-15). The results revealed that IL-15 can stimulate the immune system to cure a few types of cancers in dogs.

In September 2023, as per FidoCure, various precision medicine tools are offering veterinarians new hope for understanding hemangiosarcoma (HSA), a common aggressive canine cancer. HSA diagnosis is a devastating development for dog owners, on account of the diagnosis process being very lengthy and painful. Thus, hemangiosarcoma genomic sequencing can provide data that aids veterinarians in understanding the prognosis of HSA patients better and enable pet parents to make informed decisions with regard to life and death decisions for their pets.

Animal Type Insights

Based on animal type, the canine segment held the leading revenue share of over 85.00% in 2022. The continued growth in the global pet dog population, as well as rising prevalence of cancer and an increasing awareness regarding treatment options have led to the segment's dominant share. Furthermore, the market is anticipated to grow due to increased corporate investments in canine cancer therapies. Companies are utilizing strategies such as R&D partnerships, licensing, and business growth, in order to improve their product portfolio in canine oncology.

The feline segment is projected to expand at the fastest CAGR of 12.24% over the forecast period. The segment growth is on account of the increasing global pet cat population, as well as the rising prevalence of feline cancer and the growing instances of cat visits to the veterinary clinics. As per the Canadian Animal Health Institute (CAHI), 58% of households in Canada owned at least one dog or cat in 2022. The cat population rose to 8.5 million in 2022 from 8.1 million in 2020. CAHI also revealed that the percentage of pets receiving medical care increased significantly in 2022.

Therapy Type Insights

Based on therapy type, the market is classified into surgery, radiotherapy, immunotherapy, and chemotherapy, among other therapy segments. The surgery segment accounted for the highest share in the market of over 37.00% in 2022, which has been attributed to the growing instances of tumor removal procedures by surgeons owing to their various benefits. For a majority of animal cancer and tumor cases, surgery is the preferred treatment option.

The demand for veterinary radiotherapy is increasing in North America due to several factors, including increased pet ownership, advanced veterinary medicine, greater awareness & education, specialized veterinary facilities, insurance coverage, rising cancer rates in pets, success stories, research & innovation, quality of life considerations, and the strong human-animal bond. This growth is expected to continue as pet owners seek the best possible care for their beloved animals.

Cancer Type Insights

In terms of cancer type, the market is divided into skin cancers, lymphomas, sarcomas, and others segments.In 2022, the skin cancers segment held the largest revenue share of 39.36%. Skin tumors are more prevalent in older dogs than cats. Skin tumors are frequently benign in dogs but typically malignant in cats. Skin tumors make up about one-third of all canine tumors. Approximately 40% of all skin tumors are located on the limbs, usually the hind limbs, 40% on the body, and the remaining 20% on the head or neck.

Approximately 15% of skin tumors in dogs and 7% of skin cancers in cats are soft tissue sarcomas. Dogs frequently get fibrosarcoma, which is a kind of soft tissue sarcoma. Surgery is the most often used treatment for all soft tissue sarcomas. Wide margins (the amount of tissue that needs to be excised) are necessary for the greatest tumor control since these tumors frequently develop 'tentacles' of aberrant cells. Radiation therapy is utilized to stop or postpone the tumor's regrowth.

Country Insights

The U.S. accounted for a dominant share of over 85.0% in the market in 2022, aided by the growing focus on pet health, the presence of several notable pet drug manufacturing firms, and the adoption of innovative pet care solutions. Additionally, increased government funding for pet oncology services and the availability of established companies in the veterinary oncology space are expected to further drive market growth.

North America Veterinary Oncology market share and size, 2022

Furthermore, the rising number of veterinary cancer care centers in the country is contributing to market growth. For instance, in November 2022, The Virginia-Maryland College of Veterinary Medicine gained attention across the U.S. by opening a center dedicated to treating and studying cancer in pet animals. It has plans to expand the college's current teaching hospital to further the university's dual mission of educating students and providing clinical care for animals.

Key Companies & Market Share Insights

The North American market is fragmented and extremely competitive due to the presence of several small- and large-sized players. They are involved actively in providing new treatment modalities for pets to fight cancer through strategies such as mergers & acquisitions, collaborations, and partnerships. Established players heavily invest in R&D activities to develop innovative treatment solutions, diagnostic tools, and therapies. They partner with established veterinarians, researchers, and institutions to innovate in the field of veterinary oncology.

Moreover, these companies offer a wide range of products and services for the diagnosis, treatment, and management of cancer in pets. This diversification allows them to cater to the varying needs of veterinarians and pet owners. Innovators adopt intensive R&D initiatives to strengthen their product pipeline and market presence. The market is driven by advancements in immunotherapy, targeted therapies, and precision medicine. The increasing rate of diagnoses is expected to fuel the demand for safe and effective therapies in the near future. Some prominent players in the North America veterinary oncology market include:

  • Boehringer Ingelheim International GmbH

  • Elanco Animal Health

  • Zoetis Services LLC

  • Elekta AB

  • PetCure Oncology

  • Accuray Incorporated

  • Varian Medical Systems, Inc. (parent company: Siemens Healthineers)

  • Virbac

  • Torigen Pharmaceuticals Inc.

  • Dechra Pharmaceuticals PLC

  • NovaVive Inc.

  • Ardent Animal Health, LLC (A BreakthrU Company)

North America Veterinary Oncology Market Report Scope

Report Attribute


Market size value in 2023

USD 0.53 billion

The revenue forecast in 2033

USD 1.46 billion

Growth rate

CAGR of 10.57% from 2023 to 2033

Base year for estimation


Historical data

2018 - 2021

Forecast period

2023 - 2033

Quantitative units

Revenue in USD million/billion & CAGR from 2023 to 2033

Report coverage

Revenue forecast, company ranking, competitive landscape, growth factors, and trends

Segments covered

Animal type, therapy, cancer type, country

Regional Scope

North America

Country Scope

U.S.; Canada

Key companies profiled

Boehringer Ingelheim International GmbH; Elanco Animal Health; Zoetis Services LLC; Elekta AB; PetCure Oncology; Accuray Incorporated; Varian Medical Systems, Inc.; Virbac; Torigen Pharmaceuticals Inc.; Dechra Pharmaceuticals PLC; NovaVive Inc.; Ardent Animal Health, LLC (A BreakthrU Company)

Customization scope

Free report customization (equivalent up to 8 analysts’ working days) with purchase. Addition or alteration to country, regional & segment scope.

Pricing and purchase options

Avail customized purchase options to meet your exact research needs. Explore purchase options


North America Veterinary Oncology Market Report Segmentation

This report forecasts revenue growth at the regional & country level and provides an analysis of the latest trends and opportunities in each of the sub-segments from 2018 to 2033. For this report, Grand View Research has segmented the North America veterinary oncology market report based on animal type, therapy, cancer type, and country:

  • Animal Type Outlook (Revenue, USD Million, 2018 - 2033)

    • Canine

    • Feline

    • Equine

  • Therapy Outlook (Revenue, USD Million, 2018 - 2033)

    • Radiotherapy

      • Stereotactic Radiation Therapy

        • LINAC

        • Other Types

      • Conventional Radiation Therapy

    • Surgery

    • Chemotherapy

    • Immunotherapy

    • Other Therapies

  • Cancer Type Outlook (Revenue, USD Million, 2018 - 2033)

    • Skin Cancers

    • Lymphomas

    • Sarcomas

    • Others

  • Country Outlook (Revenue, USD Million, 2018 - 2033)

    • U.S.

    • Canada

Frequently Asked Questions About This Report

gvr icn


gvr icn

This FREE sample includes data points, ranging from trend analyses to estimates and forecasts. See for yourself.

gvr icn


We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities. Contact us now

Certified Icon

We are GDPR and CCPA compliant! Your transaction & personal information is safe and secure. For more details, please read our privacy policy.